Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28007472 | 0.89 | TSHR (0.69) | ALDH1A1TSHRMAPK1ANPEPERAP2 | |
| SCHEMBL13777020 | 0.84 | ALDH1A1 (0.45) | ALDH1A1TSHRMAPK1ANPEPERAP2 | |
| SCHEMBL28772767 | 0.84 | ALDH1A1 (0.45) | ALDH1A1TSHRMAPK1ANPEPERAP2 | |
| SCHEMBL799854 | 0.84 | ALDH1A1 (0.45) | ALDH1A1TSHRMAPK1ANPEPERAP2 | |
| SCHEMBL24269491 | 0.82 | — | — | |
| SCHEMBL12603758 | 0.82 | — | — | |
| SCHEMBL635314 | 0.82 | — | — | |
| SCHEMBL16556492 | 0.82 | — | — | |
| SCHEMBL8181574 | 0.82 | — | — | |
| SCHEMBL1774475 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009109492-A1 | DYEING AUXILIARY | CLARIANT INTERNATIONAL LTD (CH) | 2009-09-11 | — | — | WO | claimed |
| EP-1468038-A1 | METHOD FOR PRODUCING ALKALINE POLYCONDENSATION PRODUCTS | CHT R. BEITLICH GmbH (DE) | 2004-10-20 | — | — | EP | claimed |
| WO-2003062304-A1 | METHOD FOR PRODUCING ALKALINE POLYCONDENSATION PRODUCTS | CHT R. BEITLICH GMBH (DE) | 2003-07-31 | — | — | WO | claimed |
| US-20190142798-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS | 2019-05-16 | — | — | US | disclosed |
| US-9085715-B2 | Process for assembling two surfaces or one surface with a molecule of interest | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2015-07-21 | — | — | US | disclosed |
| US-20090286308-A1 | Process for assembling two surfaces or one surface with a molecule of interest | COMMISSARIAT A L' ENERGIE ATOMIQUE | 2009-11-19 | — | — | US | disclosed |
| WO-2008005752-A2 | MODIFICATION OF SURFACES OF POLYMERIC ARTICLES BY MICHAEL ADDITION REACTION | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080003259-A1 | Modification of surfaces of polymeric articles by Michael addition reaction | BAUSCH & LOMB INCORPORATED | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142798-A1 | POLYMER-DES-ETHYL SUNITINIB CONJUGATES | KDR, FLT4, FLT1 | ALDH1A1 3041/4885TSHR 3176/4885MAPK1 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.